Evidence map›Paper›PMID 34615900›Full record

ArticleScientific reports2021

Activators of alpha synuclein expression identified by reporter cell line-based high throughput drug screen.

Fabian Stahl, Philip Denner, Dominik Piston, Bernd O Evert, Laura de Boni, Ina Schmitt, Peter Breuer, Ullrich Wüllner

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fabian StahlDZNE, German Center for Neurodegenerative Diseases, Venusberg-Campus 1/99, 53127, Bonn, Germany.
Philip DennerDZNE, German Center for Neurodegenerative Diseases, Venusberg-Campus 1/99, 53127, Bonn, Germany.
Dominik PistonDZNE, German Center for Neurodegenerative Diseases, Venusberg-Campus 1/99, 53127, Bonn, Germany.
Bernd O EvertDepartment of Neurology, University Hospital Bonn, 53127, Bonn, Germany.
Laura de BoniDepartment of Neurology, University Hospital Bonn, 53127, Bonn, Germany.
Ina SchmittDepartment of Neurology, University Hospital Bonn, 53127, Bonn, Germany.
Peter BreuerDepartment of Neurology, University Hospital Bonn, 53127, Bonn, Germany. peter.breuer@ukbonn.de.
Ullrich WüllnerDZNE, German Center for Neurodegenerative Diseases, Venusberg-Campus 1/99, 53127, Bonn, Germany. ullrich.wuellner@dzne.de.
University Hospital Bonn · DEGerman Center for Neurodegenerative Diseases · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiplications, mutations and dysregulation of the alpha synuclein gene (SNCA) are associated with the demise of dopaminergic neurons and are considered to play important roles in the pathogenesis of familial and sporadic forms of Parkinson's disease. Regulation of SNCA expression might thus be an appropriate target for treatment. We aimed to identify specific modulators of SNCA transcription, generated CRISPR/Cas9 modified SNCA-GFP-luciferase (LUC) genomic fusion- and control cell lines and screened a library of 1649 bioactive compounds, including the FDA approved drugs. We found no inhibitors but three selective activators which increased SNCA mRNA and protein levels.

Indexed as

Drug DiscoveryHigh-Throughput Screening Assaysalpha-SynucleinCell LineDNA MethylationGene ExpressionGene Expression RegulationGenes, ReporterHistonesHumansSmall Molecule Librariesalpha-SynucleinHistonesSmall Molecule LibrariesSNCA protein, human

Identifiers

PMID34615900
PMCPMC8494889
OpenAlexW3169738316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.